Research
Hormonal
Semaglutide was associated with a reduction in heavy drinking days by -41.1 percentage points from baseline compared to placebo, which had a reduction of -26.4 percentage points.
Semaglutide may be a viable treatment option for reducing heavy drinking in patients with alcohol use disorder and obesity.
StrongSupportsmedium confidence
Semaglutide was associated with a reduction in heavy drinking days (-41·1 percentage points from baseline, 95% CI -48·7 to -33·5) compared with placebo (-26·4, -34·1 to -18·6; estimated treatment difference -13·7 percentage points, -22·0 to -5·4; p=0·0015).
Why this rating
Based on the randomized, double-blind, placebo-controlled trial design.
Source
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
Mette Kruse Klausen et al. · The Lancet · 2026
rct · n=108Cited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →